BG101858A - Powder carrier for usage in dry inhalers - Google Patents

Powder carrier for usage in dry inhalers

Info

Publication number
BG101858A
BG101858A BG101858A BG10185897A BG101858A BG 101858 A BG101858 A BG 101858A BG 101858 A BG101858 A BG 101858A BG 10185897 A BG10185897 A BG 10185897A BG 101858 A BG101858 A BG 101858A
Authority
BG
Bulgaria
Prior art keywords
usage
inhaler
powder carrier
carrier
dry
Prior art date
Application number
BG101858A
Other languages
Unknown language ( )
Bulgarian (bg)
English (en)
Inventor
John Staniforth
Original Assignee
Coordinated Drug Development Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10768844&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG101858(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Coordinated Drug Development Limited filed Critical Coordinated Drug Development Limited
Publication of BG101858A publication Critical patent/BG101858A/

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BG101858A 1995-01-31 1997-08-27 Powder carrier for usage in dry inhalers BG101858A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9501841.2A GB9501841D0 (en) 1995-01-31 1995-01-31 Improvements in and relating to carrier particles for use in dry powder inhalers
GBGB9521937.4A GB9521937D0 (en) 1995-01-31 1995-10-26 Improvementsin and relating to carrier particles for use in dry powder inhailers
PCT/GB1996/000215 WO1996023485A1 (en) 1995-01-31 1996-01-31 Carrier particles for use in dry powder inhalers

Publications (1)

Publication Number Publication Date
BG101858A true BG101858A (en) 1998-04-30

Family

ID=10768844

Family Applications (1)

Application Number Title Priority Date Filing Date
BG101858A BG101858A (en) 1995-01-31 1997-08-27 Powder carrier for usage in dry inhalers

Country Status (33)

Country Link
US (5) US6153224A (tr)
EP (6) EP1232745B1 (tr)
JP (1) JP4042867B2 (tr)
KR (1) KR100500694B1 (tr)
CN (1) CN1303974C (tr)
AT (3) ATE256450T1 (tr)
AU (1) AU699131B2 (tr)
BG (1) BG101858A (tr)
BR (3) BRPI9612950B8 (tr)
CA (1) CA2211874C (tr)
CZ (1) CZ294259B6 (tr)
DE (2) DE69631119T2 (tr)
DK (3) DK1666023T3 (tr)
EA (1) EA000352B1 (tr)
EE (1) EE9700176A (tr)
ES (3) ES2213172T3 (tr)
FI (1) FI119676B (tr)
GB (2) GB9501841D0 (tr)
GE (1) GEP19991687B (tr)
HK (1) HK1084897A1 (tr)
HU (1) HU229965B1 (tr)
IS (1) IS4531A (tr)
MX (1) MX9705847A (tr)
NO (1) NO324037B1 (tr)
NZ (1) NZ300654A (tr)
PL (1) PL186757B1 (tr)
PT (3) PT1232745E (tr)
SI (2) SI1232745T1 (tr)
SK (1) SK282630B6 (tr)
TR (1) TR199700722T1 (tr)
UA (1) UA61051C2 (tr)
WO (1) WO1996023485A1 (tr)
ZA (1) ZA96721B (tr)

Families Citing this family (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6743777B1 (en) * 1992-03-19 2004-06-01 Eli Lilly And Company Cyclic peptide antifungal agents and process for preparation thereof
GB9322014D0 (en) * 1993-10-26 1993-12-15 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
GB9515182D0 (en) * 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
AUPN661995A0 (en) 1995-11-16 1995-12-07 Memtec America Corporation Electrochemical cell 2
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5871010A (en) * 1996-06-10 1999-02-16 Sarnoff Corporation Inhaler apparatus with modified surfaces for enhanced release of dry powders
US7052678B2 (en) 1997-09-15 2006-05-30 Massachusetts Institute Of Technology Particles for inhalation having sustained release properties
GB9806477D0 (en) * 1998-03-26 1998-05-27 Glaxo Group Ltd Improved crystals
US6956021B1 (en) 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
HU226164B1 (en) * 1998-11-13 2008-05-28 Jagotec Ag Use of magnesium stearate in dry powder compositions suitable for inhalation and compositions suitable for inhalation
US20070212422A1 (en) * 1999-11-10 2007-09-13 Manfred Keller Dry powder for inhalation
GB9827145D0 (en) * 1998-12-09 1999-02-03 Co Ordinated Drug Dev Improvements in or relating to powders
EP1156782B1 (en) * 1999-03-03 2005-05-04 Eli Lilly And Company Echinocandin pharmaceutical formulations containing micelle-forming surfactants
EP1157030B1 (en) * 1999-03-03 2003-08-27 Eli Lilly And Company Echinocandin/carbohydrate complexes
HUP0200185A3 (en) 1999-03-05 2006-07-28 Chiesi Farma Spa Improved powdery pharmaceutical compositions for inhalation
IT1309592B1 (it) * 1999-03-05 2002-01-24 Chiesi Farma Spa Particelle veicolo modificate da utilizzarsi nella preparazione diformulazioni farmaceutiche sotto forma di polimeri per inalazione e
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
ITMI991582A1 (it) 1999-07-16 2001-01-16 Chiesi Farma Spa Polveri costituite da particelle aventi la superficie perfettamente levigata da utilizzare come veicoli per la preparazione di miscele inala
US20010036481A1 (en) * 1999-08-25 2001-11-01 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
US7252840B1 (en) 1999-08-25 2007-08-07 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles
US6749835B1 (en) 1999-08-25 2004-06-15 Advanced Inhalation Research, Inc. Formulation for spray-drying large porous particles
US6586008B1 (en) 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
EP1238661A1 (en) * 1999-10-12 2002-09-11 Kaken Pharmaceutical Co., Ltd. Powdery inhalational preparations and process for producing the same
EP1129705A1 (en) 2000-02-17 2001-09-05 Rijksuniversiteit te Groningen Powder formulation for inhalation
HUP0300491A2 (en) * 2000-02-28 2003-07-28 Vectura Ltd Improvements in or relating to the delivery of oral drugs
AU2001249479A1 (en) * 2000-04-11 2001-10-23 Dura Pharmaceuticals, Inc. Physically stabilized dry powder formulations
PE20011227A1 (es) * 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0009469D0 (en) 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formalities for use in inhaler devices
GB0009468D0 (en) * 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formulations for use in inhaler devices
CA2406206C (en) * 2000-04-17 2012-03-20 Vectura Limited Improvements in or relating to formulations for use in inhaler devices
WO2002000197A1 (en) * 2000-06-27 2002-01-03 Vectura Limited Method of making particles for use in a pharmaceutical composition
CA2413692C (en) * 2000-06-27 2011-10-18 Vectura Limited Method of making particles for use in a pharmaceutical composition
EP1326642A2 (en) * 2000-09-29 2003-07-16 Board of Trustees operating Michigan State University Catecholamine pharmaceutical compositions and methods
DK2283818T3 (en) † 2000-11-30 2017-10-16 Vectura Ltd Process for preparing particles for use in a pharmaceutical composition
AU2002215114A1 (en) * 2000-11-30 2002-06-11 Vectura Limited Pharmaceutical compositions for inhalation
EP2292212A3 (en) 2000-11-30 2012-08-08 Vectura Limited Method of making particles for use in a pharmaceutical composition
PT1920763E (pt) 2000-11-30 2014-06-25 Vectura Ltd Composições farmacêuticas para inalação
GB0030074D0 (en) * 2000-12-08 2001-01-24 Univ London Pharmacy Particulate inhalation carrier
WO2002056948A1 (en) 2001-01-17 2002-07-25 Vectura Limited An inhaler device
EG24184A (en) * 2001-06-15 2008-10-08 Otsuka Pharma Co Ltd Dry powder inhalation system for transpulmonary
US6681768B2 (en) 2001-06-22 2004-01-27 Sofotec Gmbh & Co. Kg Powder formulation disintegrating system and method for dry powder inhalers
WO2003024396A2 (en) 2001-09-17 2003-03-27 Glaxo Group Limited Dry powder medicament formulations
WO2003043603A1 (en) * 2001-11-20 2003-05-30 Advanced Inhalation Research, Inc. Particulate compositions for improving solubility of poorly soluble agents
CA2465675C (en) * 2001-11-20 2008-06-10 Advanced Inhalation Research, Inc. Improved particulate compositions for pulmonary delivery
US7641823B2 (en) * 2001-12-07 2010-01-05 Map Pharmaceuticals, Inc. Synthesis of small particles
EP1490031A1 (en) 2002-03-07 2004-12-29 Vectura Limited Fast melt multiparticulate formulations for oral delivery
US7754242B2 (en) * 2002-03-20 2010-07-13 Alkermes, Inc. Inhalable sustained therapeutic formulations
AU2006220411B2 (en) * 2002-03-20 2008-06-26 Alkermes, Inc. Inhalable Sustained Therapeutic Formulations
CA2478974C (en) * 2002-03-20 2014-12-16 Advanced Inhalation Research, Inc. Inhalable sustained therapeutic formulations
GB0210527D0 (en) * 2002-05-08 2002-06-19 Univ Bath Process for the treatment of particles for use in pharmaceutical formulations
US6991800B2 (en) * 2002-06-13 2006-01-31 Vicuron Pharmaceuticals Inc. Antifungal parenteral products
GB0219511D0 (en) * 2002-08-21 2002-10-02 Norton Healthcare Ltd Method of preparing dry powder inhalation compositions
AU2003269989B8 (en) * 2002-08-21 2009-11-12 Norton Healthcare Ltd. Inhalation composition
US20050158248A1 (en) * 2002-08-21 2005-07-21 Xian-Ming Zeng Method of preparing dry powder inhalation compositions
AU2003279070A1 (en) * 2002-09-30 2004-04-23 Acusphere Inc Sustained release porous microparticles for inhalation
JP5154078B2 (ja) * 2003-02-21 2013-02-27 ザ ユニヴァーシティ オブ バース 粒子の製造プロセス
AU2004231342A1 (en) 2003-04-14 2004-11-04 Vectura Ltd Dry power inhaler devices and dry power formulations for enhancing dosing efficiency
US20050026886A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a PDE IV inhibitor
US20050026948A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
GB0321607D0 (en) 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
WO2005025535A2 (en) * 2003-09-15 2005-03-24 Vectura Limited Methods for preparing pharmaceutical compositions
GB0326632D0 (en) 2003-11-14 2003-12-17 Jagotec Ag Dry powder formulations
BRPI0510119A (pt) 2004-04-23 2007-09-25 Cydex Inc formulação para dpi contendo sulfoaquil éter de ciclodextrina
GB0409703D0 (en) 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
WO2006055950A1 (en) * 2004-11-18 2006-05-26 Nektar Therapeutics Pharmaceutical dry powder formulation on the basis particles comprising multiple active agents
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
WO2006086270A1 (en) * 2005-02-10 2006-08-17 Glaxo Group Limited Processes for making lactose utilizing pre-classification techniques and pharmaceutical formulations formed therefrom
US8524734B2 (en) 2005-05-18 2013-09-03 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
JP5279487B2 (ja) 2005-05-18 2013-09-04 エムペックス・ファーマシューティカルズ・インコーポレーテッド エアロゾル化フルオロキノロンおよびその使用
ITMI20051999A1 (it) 2005-10-21 2007-04-22 Eratech S R L Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
WO2007053923A2 (en) * 2005-11-11 2007-05-18 Biolab Sanus Farmacêutica Ltda. Solid pharmaceutical composition comprising agglomerate nanoparticles and a process for producing the same
GB0525254D0 (en) 2005-12-12 2006-01-18 Jagotec Ag Powder compositions for inhalation
JP2009519972A (ja) * 2005-12-15 2009-05-21 アキュスフィア， インコーポレイテッド 粒子ベースの経肺投与または経鼻投与用製薬の製造方法
GB0602897D0 (en) * 2006-02-13 2006-03-22 Jagotec Ag Improvements In Or Relating To Dry Powder Inhaler Devices
AU2007224178B2 (en) * 2006-03-03 2013-03-07 Stc.Unm Dry powder inhaler with aeroelastic dispersion mechanism
GB0613161D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
GB0622818D0 (en) * 2006-11-15 2006-12-27 Jagotec Ag Improvements in or relating to organic compounds
GB0625303D0 (en) * 2006-12-19 2007-01-24 Jagotec Ag Improvements in and relating to metered dose inhalers
WO2008134817A1 (en) * 2007-05-03 2008-11-13 The University Of Sydney Composite carriers for dry powder inhalation therapy
US20090048155A1 (en) 2007-08-15 2009-02-19 Endacea, Inc. Methods for preventing and treating tissue injury and sepsis associated with Yersinia pestis infection
GB0721394D0 (en) * 2007-10-31 2007-12-12 Vectura Group Plc Compositions for trating parkinson's disease
JP5603248B2 (ja) 2007-12-21 2014-10-08 エンダセア， インコーポレイテッド Ａ１アデノシン受容体アンタゴニスト
GB0801876D0 (en) * 2008-02-01 2008-03-12 Vectura Group Plc Suspension formulations
NO2252275T3 (tr) 2008-02-13 2018-04-28
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
US9072664B2 (en) * 2008-05-22 2015-07-07 3M Innovative Properties Company Process for manufacturing flowable powder drug compositions
WO2009158300A1 (en) * 2008-06-26 2009-12-30 3M Innovative Properties Company Dry powder pharmaceutical compositions for pulmonary administration, and methods of manufacturing thereof
WO2010002613A2 (en) * 2008-07-02 2010-01-07 3M Innovative Properties Company Method of making a dry powder pharmaceutical composition
US20110253140A1 (en) * 2008-07-30 2011-10-20 Stc.Unm Formulations containing large-size carrier particles for dry powder inhalation aerosols
ES2809177T3 (es) 2008-10-07 2021-03-03 Horizon Orphan Llc Inhalación de levofloxacino para reducir la inflamación pulmonar
LT2344129T (lt) 2008-10-07 2018-05-10 Horizon Orphan Llc Aerozolinės fluorchinolono kompozicijos, skirtos farmakokinetikų pagerinimui
US11116721B2 (en) 2009-02-26 2021-09-14 Glaxo Group Limited Pharmaceutical formulations comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol
CN102458372A (zh) * 2009-04-24 2012-05-16 先灵公司 适用在干粉吸入器中的聚结物制剂
RU2563809C2 (ru) 2009-09-04 2015-09-20 Мпекс Фармасьютикалс, Инк. Применение левофлоксацина в форме аэрозоля для лечения муковисцидоза
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
US9492625B2 (en) 2009-11-12 2016-11-15 Stc.Unm Dry powder inhaler with flutter dispersion member
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
GB0921481D0 (en) 2009-12-08 2010-01-20 Vectura Ltd Process and product
US9877967B2 (en) 2010-01-26 2018-01-30 Endacea, Inc. Methods and pharmaceutical compositions for preventing and treating renal impairment
AU2011244384B2 (en) 2010-04-21 2016-06-23 Chiesi Farmaceutici S.P.A. "Process for providing particles with reduced electrostatic charges"
UY33337A (es) 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
TW201304822A (zh) 2010-11-15 2013-02-01 Vectura Ltd 組成物及用途
TW201306847A (zh) 2010-11-30 2013-02-16 Vectura Ltd 組成物及用途
EP2648788B1 (en) 2010-12-07 2017-08-09 Respira Therapeutics, Inc. Dry powder inhaler
EP2670242B1 (en) 2011-01-31 2022-03-16 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
JO3510B1 (ar) 2011-03-04 2020-07-05 Heptares Therapeutics Ltd استخدام جلايكوبيرولات لعلاج عدم انتظام دقات القلب
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
HUE060705T2 (hu) * 2012-01-25 2023-04-28 Chiesi Farm Spa Kortikoszteroidot és béta-adrenerg szert tartalmazó száraz porkészítmény inhalálással történõ beadásra
US9603906B2 (en) 2012-02-01 2017-03-28 Protalix Ltd. Inhalable liquid formulations of DNase I
US10463815B2 (en) 2012-02-21 2019-11-05 Respira Therapeutics, Inc. Inhaler to deliver substances for prophylaxis or prevention of disease or injury caused by the inhalation of biological or chemical agents
PE20141964A1 (es) 2012-03-13 2014-12-01 Respivert Ltd Formulaciones farmaceuticas novedosas
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
GB201305825D0 (en) 2013-03-28 2013-05-15 Vectura Ltd New use
WO2014186754A2 (en) 2013-05-16 2014-11-20 Board Of Regents The University Of Texas System Dry solid aluminum adjuvant-containing vaccines and related methods thereof
US20150044288A1 (en) 2013-07-31 2015-02-12 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
US9427376B2 (en) * 2013-10-10 2016-08-30 Chiesi Farmaceutici S.P.A. Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient
NZ722927A (en) 2014-01-10 2022-07-29 Avalyn Pharma Inc Aerosol pirfenidone and pyridone analog compounds and uses thereof
ES2913486T3 (es) 2014-03-19 2022-06-02 Infinity Pharmaceuticals Inc Compuestos heterocíclicos para la utilización en el tratamiento de trastornos mediados por PI3K-gamma
WO2015179369A1 (en) 2014-05-20 2015-11-26 Infinity Pharmaceuticals, Inc. Treatment of pulmonary or respiratory diseases by inhalation administration of pi3 kinase inhibitors
WO2016038116A1 (en) 2014-09-09 2016-03-17 Vectura Limited Formulation comprising glycopyrrolate, method and apparatus
ES2841933T3 (es) 2014-10-31 2021-07-12 Univ Monash Formulación en polvo
NZ731347A (en) 2014-11-26 2018-01-26 Vectura Delivery Devices Ltd Dry powder inhaler
JP2018501903A (ja) 2015-01-14 2018-01-25 レスピラ セラピューティクス インコーポレイテッドＲｅｓｐｉｒａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． パウダー分散方法および装置
EP3340982B1 (en) 2015-08-26 2021-12-15 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
EP3689339B1 (en) 2015-09-09 2022-01-26 Vectura Limited Jet milling method
BR112018067454A2 (pt) 2016-03-08 2019-01-15 Mereo Biopharma 1 Ltd regime de dosagem para o tratamento de exacerbações agudas de doença pulmonar obstrutiva crônica
MX2018010781A (es) 2016-03-08 2018-11-09 Mereo Biopharma 1 Ltd Regimen de dosificacion para el tratamiento de exacerbaciones agudas de condiciones inflamatorias.
JP7057290B2 (ja) 2016-06-27 2022-04-19 アキリオン ファーマシューティカルズ，インコーポレーテッド 医学的障害を治療するためのキナゾリン及びインドール化合物
CA3053818A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
KR20200097311A (ko) 2017-12-11 2020-08-18 메레오 바이오파마 1 리미티드 만성 폐쇄성 폐 질환의 급성 악화의 치료에서의 3-[5-아미노-4-(3-시아노벤조일)-피라졸-1-일]-n-시클로프로필-4-메틸벤즈아미드의 용도
CA3083953A1 (en) 2017-12-11 2019-06-20 Board Of Regents, The University Of Texas System Dry adjuvanted immune stimulating compositions and use thereof for mucosal administration
KR20200097310A (ko) 2017-12-11 2020-08-18 메레오 바이오파마 1 리미티드 만성 폐쇄성 폐 질환의 급성 악화의 예방 또는 감소에서의 3-[5-아미노-4-(3-시아노벤조일)-피라졸-1-일]-n-시클로프로필-4-메틸벤즈아미드의 용도
EP3773576A4 (en) 2018-03-26 2021-12-29 C4 Therapeutics, Inc. Cereblon binders for the degradation of ikaros
EP3841086A4 (en) 2018-08-20 2022-07-27 Achillion Pharmaceuticals, Inc. PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF MEDICAL DISORDERS RELATED TO COMPLEMENT FACTOR D
WO2020081723A1 (en) 2018-10-16 2020-04-23 Georgia State University Research Foundation, Inc. Carbon monoxide prodrugs for the treatment of medical disorders
SI3947384T1 (sl) 2019-04-04 2024-03-29 Chiesi Farmaceutici S.P.A. Izokromenski derivati kot inhibitorji fosfoinozitid 3-kinaz
CN114514020A (zh) 2019-09-24 2022-05-17 奇斯药制品公司 用于吸入用干粉制剂的新型载体颗粒
WO2022047047A1 (en) * 2020-08-26 2022-03-03 Cila Therapeutic Inc. Inhalable therapeutic agents
CN112451509B (zh) * 2020-12-19 2023-03-07 沈阳药科大学 一种川丁特罗吸入粉雾剂及其制备方法
WO2022240897A1 (en) 2021-05-10 2022-11-17 Sepelo Therapeutics, Llc Pharmaceutical composition comprising delafloxacin for administration into the lung
WO2023028364A1 (en) 2021-08-27 2023-03-02 Sepelo Therapeutics, Llc Targeted compositions and uses therof
WO2023196663A1 (en) * 2022-04-07 2023-10-12 Board Of Regents, The University Of Texas System Methods of preparing carrier-based dry powders for inhalation
US12029709B2 (en) * 2022-08-11 2024-07-09 De Motu Cordis Pty Ltd Inhalable epinephrine formulation
WO2024119058A2 (en) 2022-12-02 2024-06-06 Kinaset Therapeutics, Inc. Formulation of a pan-jak inhibitor
CN115855911B (zh) * 2023-02-24 2023-06-13 湖南三友环保科技有限公司 粉末载体生物亲和性的测定方法及应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2533065A (en) * 1947-03-08 1950-12-05 George V Taplin Micropulverized therapeutic agents
GB786499A (en) * 1953-11-02 1957-11-20 Grace W R & Co A process of deagglomerating dried agglomerated microspheroidal gel catalyst particles
GB905723A (en) * 1959-12-10 1962-09-12 Alfred Ernest Tragham Pharmaceutical compositions comprising phenacitin
GB1132583A (en) * 1964-12-16 1968-11-06 Glaxo Lab Ltd Pharmaceutical compositions containing cephalosporins
US3957965A (en) * 1967-08-08 1976-05-18 Fisons Limited Sodium chromoglycate inhalation medicament
GB1242211A (en) * 1967-08-08 1971-08-11 Fisons Pharmaceuticals Ltd Pharmaceutical composition
GB1242212A (en) * 1967-08-08 1971-08-11 Fisons Pharmaceuticals Ltd Drug for use in pharmaceutical composition
GB1230087A (tr) * 1967-08-17 1971-04-28
GB1310527A (en) * 1969-06-13 1973-03-21 Fisons Ltd Comminuting apparatus
GB1381872A (en) * 1971-06-22 1975-01-29 Fisons Ltd Pharmaceutical compositions for inhalation
GB1410588A (en) * 1971-08-10 1975-10-22 Fisons Ltd Composition
IT1197640B (it) * 1983-05-03 1988-12-06 Italsil Spa Apparecchio e metodo per la purificazione di sabbie silicee mediante attrizione
EP0187433B1 (en) * 1983-08-01 1990-12-27 Teijin Limited Powdery pharmaceutical composition suitable for application to mucosa of oral or nasal cavity
IT1204826B (it) * 1986-03-04 1989-03-10 Chiesi Farma Spa Composizioni farmaceutiche per inalazione
GB9001635D0 (en) * 1990-01-24 1990-03-21 Ganderton David Aerosol carriers
US5376386A (en) * 1990-01-24 1994-12-27 British Technology Group Limited Aerosol carriers
IL97065A (en) * 1990-02-02 1994-01-25 Fisons Plc Repellent preparations for aerosol
ES2071306T3 (es) * 1990-03-23 1995-06-16 Minnesota Mining & Mfg El uso de tensioactivos fluorados solubles para la preparacion de formulaciones aerosoles dosificadas.
GB9024366D0 (en) * 1990-11-09 1991-01-02 Glaxo Group Ltd Medicaments
DE4140689B4 (de) * 1991-12-10 2007-11-22 Boehringer Ingelheim Kg Inhalationspulver und Verfahren zu ihrer Herstellung
ES2159524T3 (es) * 1992-06-12 2001-10-16 Teijin Ltd Preparacion farmaceutica para administrarse en el interior de las vias respiratorias.
DE69332240T2 (de) * 1992-06-12 2003-04-10 Teijin Ltd., Osaka Ultrafeines pulver zur inhalation und dessen herstellung
GB2269992A (en) * 1992-08-14 1994-03-02 Rh Ne Poulenc Rorer Limited Powder inhalation formulations
ZA94155B (en) 1992-11-06 1995-07-11 Adcock Ingram Pharma Pharmaceutical composition
SE9203743D0 (sv) * 1992-12-11 1992-12-11 Astra Ab Efficient use
IS1796B (is) * 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
TW402506B (en) * 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
US5506203C1 (en) * 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
GB9322014D0 (en) * 1993-10-26 1993-12-15 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
GB9515182D0 (en) * 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
HUP0200185A3 (en) * 1999-03-05 2006-07-28 Chiesi Farma Spa Improved powdery pharmaceutical compositions for inhalation
PE20011227A1 (es) * 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0009469D0 (en) * 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formalities for use in inhaler devices
WO2002000197A1 (en) * 2000-06-27 2002-01-03 Vectura Limited Method of making particles for use in a pharmaceutical composition
JP3486405B2 (ja) 2001-08-10 2004-01-13 三菱重工業株式会社 減揺装置

Also Published As

Publication number Publication date
EP0806938B1 (en) 2003-12-17
SK103697A3 (en) 1998-01-14
PL321572A1 (en) 1997-12-08
GB9521937D0 (en) 1996-01-03
GEP19991687B (en) 1999-08-05
CN1179097A (zh) 1998-04-15
PT1666023E (pt) 2012-01-12
EE9700176A (et) 1998-02-16
ATE256450T1 (de) 2004-01-15
ES2213172T3 (es) 2004-08-16
US8920781B2 (en) 2014-12-30
PT1232745E (pt) 2007-04-30
FI973151A0 (fi) 1997-07-30
SK282630B6 (sk) 2002-10-08
US20060029552A1 (en) 2006-02-09
BR9607490B8 (pt) 2018-04-17
CZ244397A3 (cs) 1998-01-14
US20030170183A1 (en) 2003-09-11
EP2258342A3 (en) 2014-01-08
AU4545696A (en) 1996-08-21
DE69636961T2 (de) 2007-06-14
BRPI9612950B8 (pt) 2018-04-17
ES2375007T3 (es) 2012-02-24
ATE355822T1 (de) 2007-03-15
CN1303974C (zh) 2007-03-14
HK1084897A1 (en) 2006-08-11
DK1232745T3 (da) 2007-07-09
US7718163B2 (en) 2010-05-18
KR19980701844A (ko) 1998-06-25
EA000352B1 (ru) 1999-04-29
US6153224A (en) 2000-11-28
EP0806938A1 (en) 1997-11-19
EP1666023A2 (en) 2006-06-07
GB9501841D0 (en) 1995-03-22
US6521260B1 (en) 2003-02-18
EA199700153A1 (ru) 1997-12-30
NO324037B1 (no) 2007-07-30
TR199700722T1 (tr) 1998-02-21
EP1666023A3 (en) 2009-05-06
PL186757B1 (pl) 2004-02-27
WO1996023485A1 (en) 1996-08-08
PT806938E (pt) 2004-05-31
ATE526946T1 (de) 2011-10-15
EP2258342A2 (en) 2010-12-08
DE69631119T2 (de) 2004-09-16
SI1666023T1 (sl) 2012-01-31
EP2213279A2 (en) 2010-08-04
MX9705847A (es) 1998-08-30
DE69636961D1 (de) 2007-04-19
KR100500694B1 (ko) 2006-03-22
DK0806938T3 (da) 2004-04-13
BR9612950B1 (pt) 2011-08-23
JP4042867B2 (ja) 2008-02-06
CA2211874A1 (en) 1996-08-08
DE69631119D1 (de) 2004-01-29
SI1232745T1 (sl) 2007-06-30
DK1666023T3 (da) 2012-01-30
NO973502L (no) 1997-09-30
ZA96721B (en) 1996-08-19
BR9607490A (pt) 2018-04-17
CA2211874C (en) 2006-08-29
EP1232745A1 (en) 2002-08-21
JPH10513174A (ja) 1998-12-15
NZ300654A (en) 1999-02-25
HUP9802209A2 (hu) 1999-02-01
AU699131B2 (en) 1998-11-26
NO973502D0 (no) 1997-07-30
HUP9802209A3 (en) 2000-06-28
FI973151A (fi) 1997-09-30
EP1159955A1 (en) 2001-12-05
IS4531A (is) 1997-07-25
EP1232745B1 (en) 2007-03-07
UA61051C2 (en) 2003-11-17
FI119676B (fi) 2009-02-13
BRPI9612950B1 (tr) 2011-08-23
EP1666023B1 (en) 2011-10-05
CZ294259B6 (cs) 2004-11-10
US20100330188A1 (en) 2010-12-30
HU229965B1 (hu) 2015-03-30
EP2213279A3 (en) 2010-10-13
ES2278828T3 (es) 2007-08-16
US7011818B2 (en) 2006-03-14

Similar Documents

Publication Publication Date Title
BG101858A (en) Powder carrier for usage in dry inhalers
AU3747993A (en) Separator for powder inhalators
GR3024468T3 (en) Inhalation powder containing antistatic agent.
GB9626233D0 (en) Medicament packaging and deliveery device
NZ336592A (en) Formulation for inhalation having a poured bulk density of from 0.28 to 0.38 g/ml comprising finely divided budesonide and a carrier
IL127449A0 (en) Inhaler apparatus with modified surfaces for enhanced release of dry powders
MX9702799A (es) Portador de medicamento para inhalador de polvo seco y proceso para formar el mismo.